Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Semaglutide (Ozempic) significantly reduces CGM glucose variability, time above range, and mean sensor glucose. Learn the expected magnitude, timeline, and monitoring strategy.
Read clinical reviewOzempic (semaglutide) lowers fasting glucose by 1.2 to 2.8 mmol/L in type 2 diabetes. Learn the mechanism, timeline, trial data from SUSTAIN, and when to check your levels.
Read clinical reviewOzempic (semaglutide) lowers fasting triglycerides by 12 to 22% in clinical trials. Learn the mechanism, timeline, expected magnitude, and monitoring schedule for triglyceride changes on semaglutide.
Read clinical reviewOzempic (semaglutide) lowers HbA1c by 1.0 to 1.8 percentage points in clinical trials. Learn the dose-response curve, when to recheck labs, and how it compares to other GLP-1 receptor agonists.
Read clinical reviewSemaglutide (Ozempic) lowers triglycerides 12-20%, reduces LDL cholesterol, and raises HDL modestly. Learn the magnitude, timeline, and monitoring schedule based on SUSTAIN and SELECT trial data.
Read clinical reviewSemaglutide 0.5 to 2.0 mg (Ozempic) typically lowers AST in people with type 2 diabetes and fatty liver disease. Learn the magnitude, timing, mechanism, and when to check your labs.
Read clinical reviewSemaglutide (Ozempic 0.5 to 2.0 mg) lowers fasting insulin by reducing hepatic glucose output, improving beta-cell efficiency, and cutting insulin resistance. Learn the magnitude, time course, and monitoring implications backed by RCT data.
Read clinical review